Research programme: respiratory disease therapy - Archemix

Drug Profile

Research programme: respiratory disease therapy - Archemix

Alternative Names: Anti-IgE aptamers - Archemix

Latest Information Update: 27 Apr 2007

Price : $50

At a glance

  • Originator Archemix Corporation
  • Class
  • Mechanism of Action Fc receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Allergic rhinitis; Asthma; Peanut hypersensitivity

Most Recent Events

  • 17 Aug 2005 This programme is still in active development - (BIO-2005)
  • 27 Jul 2004 Preclinical trials in Asthma in USA (SC)
  • 27 Jul 2004 Preclinical trials in Allergic rhinitis in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top